EP4134366A4 - 3-azabicycloalkyl-derivat und pharmazeutische zusammensetzung damit - Google Patents
3-azabicycloalkyl-derivat und pharmazeutische zusammensetzung damit Download PDFInfo
- Publication number
- EP4134366A4 EP4134366A4 EP21793225.0A EP21793225A EP4134366A4 EP 4134366 A4 EP4134366 A4 EP 4134366A4 EP 21793225 A EP21793225 A EP 21793225A EP 4134366 A4 EP4134366 A4 EP 4134366A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- azabicycloalkyl
- derivative
- pharmaceutical composition
- composition containing
- containing same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200047190 | 2020-04-20 | ||
PCT/KR2021/004887 WO2021215765A1 (ko) | 2020-04-20 | 2021-04-19 | 3-아자바이사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4134366A1 EP4134366A1 (de) | 2023-02-15 |
EP4134366A4 true EP4134366A4 (de) | 2023-10-11 |
Family
ID=78232792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21793225.0A Pending EP4134366A4 (de) | 2020-04-20 | 2021-04-19 | 3-azabicycloalkyl-derivat und pharmazeutische zusammensetzung damit |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230203008A1 (de) |
EP (1) | EP4134366A4 (de) |
JP (1) | JP2023522725A (de) |
KR (1) | KR102614659B1 (de) |
CN (1) | CN115667244B (de) |
TW (1) | TWI810550B (de) |
WO (1) | WO2021215765A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220127839A (ko) * | 2019-12-24 | 2022-09-20 | 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 | Khk 억제 효과를 갖는 화합물 |
WO2022022476A1 (zh) * | 2020-07-28 | 2022-02-03 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂的盐、晶型及其用途 |
US20240067633A1 (en) * | 2020-12-25 | 2024-02-29 | Sichuan Haisco Pharmaceutical Co., Ltd. | Ketohexokinase inhibitor and use thereof |
WO2023151473A1 (zh) * | 2022-02-09 | 2023-08-17 | 上海研健新药研发有限公司 | 一种khk抑制剂,其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA032081B1 (ru) * | 2014-12-08 | 2019-04-30 | Янссен Сайенсиз Айрлэнд Юси | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) |
SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
KR102558308B1 (ko) * | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
EP3919484B1 (de) * | 2019-01-29 | 2023-05-24 | Shandong Xuanzhu Pharma Co., Ltd. | Hexon-glucokinase-inhibitor und seine verwendung |
-
2021
- 2021-04-19 US US17/996,634 patent/US20230203008A1/en active Pending
- 2021-04-19 KR KR1020210050451A patent/KR102614659B1/ko active IP Right Grant
- 2021-04-19 TW TW110113936A patent/TWI810550B/zh active
- 2021-04-19 JP JP2022564050A patent/JP2023522725A/ja active Pending
- 2021-04-19 WO PCT/KR2021/004887 patent/WO2021215765A1/ko unknown
- 2021-04-19 EP EP21793225.0A patent/EP4134366A4/de active Pending
- 2021-04-19 CN CN202180036112.0A patent/CN115667244B/zh active Active
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
CN115667244A (zh) | 2023-01-31 |
TW202202492A (zh) | 2022-01-16 |
WO2021215765A1 (ko) | 2021-10-28 |
KR20210129607A (ko) | 2021-10-28 |
CN115667244B (zh) | 2024-04-12 |
US20230203008A1 (en) | 2023-06-29 |
TWI810550B (zh) | 2023-08-01 |
KR102614659B1 (ko) | 2023-12-19 |
EP4134366A1 (de) | 2023-02-15 |
JP2023522725A (ja) | 2023-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4134366A4 (de) | 3-azabicycloalkyl-derivat und pharmazeutische zusammensetzung damit | |
EP4105211A4 (de) | Pyrimidoheterocyclische verbindungen und anwendung davon | |
EP4003369A4 (de) | Adenosinderivat und pharmazeutische zusammensetzung damit | |
EP3762392A4 (de) | Thienopyridinderivate und pharmazeutische zusammensetzung damit | |
EP3828183A4 (de) | Sulfoximinverbindung als inhibitor der bromodomäne und pharmazeutische zusammensetzung und deren medizinische verwendung | |
EP4011885A4 (de) | Oxo-pyridin-fusionsringderivate und diese umfassende pharmazeutische zusammensetzung | |
EP3842423A4 (de) | 3-azabicyclo[3,1,1]heptan-derivate und pharmazeutische zusammensetzung damit | |
EP4051241A4 (de) | Pharmazeutische zusammensetzungen aus albumin und rapamycin | |
EP4023227A4 (de) | Pharmazeutische zusammensetzung und verabreichung davon | |
EP4073071A4 (de) | Verwendung und pharmazeutische zusammensetzung von phenylisoxazolylmethylen-naphthalen-ether-derivaten | |
EP4005591A4 (de) | Antineoplastische kombinierte pharmazeutische zusammensetzung und ihre verwendung | |
EP3777866A4 (de) | Pharmazeutische zusammensetzung und verabreichung davon | |
EP4032529A4 (de) | Pharmazeutische sorafenib-zusammensetzung mit hoher bioverfügbarkeit und verwendung davon | |
EP3696176A4 (de) | Neuartiges phenylpyridinderivat und pharmazeutische zusammensetzung damit | |
EP4023638A4 (de) | Indolcarboxamidderivat und dieses enthaltende pharmazeutische zusammensetzung | |
EP3915986A4 (de) | Heteroarylderivate und pharmazeutische zusammensetzung damit als wirkstoff | |
EP4059501A4 (de) | Substituierte crotonamid-pharmazeutische zusammensetzung und herstellungsverfahren dafür | |
EP4056558A4 (de) | Indazolverbindung, pharmazeutische zusammensetzung davon und anwendungen davon | |
EP3960741A4 (de) | Chinolinverbindungen und pharmazeutische zusammensetzungen und deren verwendungen | |
EP3805210A4 (de) | Neue verbindung und pharmazeutische zusammensetzung damit | |
EP4180040A4 (de) | Pharmazeutische zusammensetzung und anwendung davon | |
EP3981422A4 (de) | Pharmazeutische zusammensetzung mit lysozym und verwendung davon | |
EP4144729A4 (de) | Zusammensetzung und verbindung | |
EP4023647A4 (de) | Imidazopyridinlderivate und pharmazeutische zusammensetzung damit als wirkstoff | |
EP4070791A4 (de) | Pharmazeutische zusammensetzung mit steroidverbindung und olopatadin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230908 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/04 20060101ALI20230904BHEP Ipc: A61P 1/16 20060101ALI20230904BHEP Ipc: A61P 3/10 20060101ALI20230904BHEP Ipc: A61P 3/00 20060101ALI20230904BHEP Ipc: A61K 31/517 20060101ALI20230904BHEP Ipc: A61K 31/519 20060101ALI20230904BHEP Ipc: A61K 31/436 20060101ALI20230904BHEP Ipc: A61K 31/4725 20060101ALI20230904BHEP Ipc: A61K 31/439 20060101ALI20230904BHEP Ipc: C07D 401/14 20060101AFI20230904BHEP |